Invention Grant
- Patent Title: 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
-
Application No.: US15104659Application Date: 2014-12-03
-
Publication No.: US09695171B2Publication Date: 2017-07-04
- Inventor: Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest , Antonia Friederike Stepan
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent John A. Wichtowski
- International Application: PCT/IB2014/066563 WO 20141203
- International Announcement: WO2015/092592 WO 20150625
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D487/04 ; C07D519/00 ; C07D491/08 ; C07D498/08
![3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors](/abs-image/US/2017/07/04/US09695171B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Public/Granted literature
Information query